In context
Murepavadin was used in original antibacterial research to alter lipopolysaccharide transport and investigate a combination approach with colistin. [1]
At a glance
- Type
- Peptide / related experimental research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- A mechanistic bacterial experiment does not establish the efficacy or safety of a clinical antibiotic regimen. Antibiotic use requires organism- and patient-specific decisions.
How to interpret this evidence
A mechanistic bacterial experiment does not establish the efficacy or safety of a clinical antibiotic regimen. Antibiotic use requires organism- and patient-specific decisions. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. pubmed.ncbi.nlm.nih.gov